These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9248605)

  • 1. Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime.
    Hitt CM; Nightingale CH; Quintiliani R; Nicolau DP
    Am J Health Syst Pharm; 1997 Jul; 54(14):1614-8. PubMed ID: 9248605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.
    Florea NR; Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
    Am J Health Syst Pharm; 2003 Nov; 60(22):2321-7. PubMed ID: 14652981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An assessment of the hidden and total antibiotic costs of four parenteral cephalosporins.
    Smyth ET; Barr JG; O'Neill CA; Hogg GM
    Pharmacoeconomics; 1995 Dec; 8(6):541-50. PubMed ID: 10160082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections].
    Martínez Jabaloyas JM; Sanz Chinesta S; Jiménez Cruz JF; Flores Corral N; Unda Urzaiz M; Leiva Galvis O; González Romojaro V; Hernández Fernández C; Lledó García E; Rioja Sanz LA; Gonzalvo Ibarra A; Camacho González JE; Ruíz Alvárez-Cienfuegos F; Resel Estévez L; Corral Saleta J; Burgos Rodríguez R; Del Rosal Samaniego JM
    Actas Urol Esp; 1997; 21(7):668-74. PubMed ID: 9412209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. A pharmaco-economic study based on a meta-analysis.
    Wessels F; Anderson AN; Ebrahim O
    S Afr Med J; 1998 Mar; 88(3):251-5. PubMed ID: 9608289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic exchange of cefotaxime for ceftriaxone: evaluation, implementation, and subsequent cost savings at a 300-bed community hospital.
    Rawlings RD
    Diagn Microbiol Infect Dis; 1995; 22(1-2):235-7. PubMed ID: 7587046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study of cefotaxime versus ceftriaxone for uncomplicated gonorrhea.
    Mogabgab WJ; Lutz FB
    South Med J; 1994 Apr; 87(4):461-4. PubMed ID: 8153771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefotaxime and ceftriaxone use evaluation in pediatrics. Considerations of cost effectiveness.
    Lee CK; Glenn DJ
    Diagn Microbiol Infect Dis; 1995; 22(1-2):231-3. PubMed ID: 7587045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The total process cost of parenteral antibiotic therapy: beyond drug acquisition cost.
    Hotchkies L; Grima DT; Hedayati S
    Clin Ther; 1996; 18(4):716-25; discussion 702. PubMed ID: 8879899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness evaluation of 3 antimicrobial regimens for the prevention of infective complications after abdominal surgery.
    Anderson G; Boldiston C; Woods S; O'Brien P
    Arch Surg; 1996 Jul; 131(7):744-8. PubMed ID: 8678775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefotaxime twice daily versus ceftriaxone once daily. A randomized controlled study in patients with serious infections.
    Simmons BP; Gelfand MS; Grogan J; Craft B
    Diagn Microbiol Infect Dis; 1995; 22(1-2):155-7. PubMed ID: 7587031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the cost-effectiveness of treatment with third-generation cephalosporins.
    Gladen HE
    Diagn Microbiol Infect Dis; 1992 Jan; 15(1):99-105. PubMed ID: 1730191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness analysis of ceftriaxone and cefotaxime in the treatment of community-acquired pneumonia].
    García-Contreras F; Del-Angel-García G; Ramírez Cuenca A; Malváez-Valdes M; Vega Yáñez A; Amato D
    Rev Invest Clin; 2000; 52(4):418-26. PubMed ID: 11061104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness decision analysis of intramuscular ceftriaxone versus oral cefixime in adolescents with gonococcal cervicitis.
    Friedland LR; Kulick RM; Biro FM; Patterson A
    Ann Emerg Med; 1996 Mar; 27(3):299-304. PubMed ID: 8599487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of hospital costs and administration of prophylactic antibiotherapy in gynecological surgery.
    Hell-Türler KT
    Isr J Med Sci; 1992 Oct; 28(10):751. PubMed ID: 1399513
    [No Abstract]   [Full Text] [Related]  

  • 17. A cost comparison of intravenous cimetidine delivery systems.
    Jackson CW; Caldwell RD; Arford PD
    Hosp Pharm; 1990 Dec; 25(12):1085-9. PubMed ID: 10108250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer.
    Pession A; Prete A; Paolucci G
    Chemotherapy; 1997; 43(5):358-66. PubMed ID: 9309370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of the clinical and economic outcomes of twice-daily dosing of cefotaxime in a Canadian tertiary care institution.
    Tin LY; Pitre M; Conly JM
    Diagn Microbiol Infect Dis; 1995; 22(1-2):135-40. PubMed ID: 7587028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for cost-containment: once-daily ceftriaxone plus amikacin as empiric therapy for febrile granulocytopenic children with cancer.
    Castagnola E; Lanino E; Giacchino R; Viscoli C; Dini G
    J Chemother; 1999 Feb; 11(1):54-60. PubMed ID: 10078782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.